Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Medexus Pharmaceuticals Inc MEDXF


Primary Symbol: T.MDP

Healthcare
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:MDP)

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Newsfile April 2, 2024

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Newsfile March 26, 2024

Medexus Announces Fiscal Q3 2024 Results

Newsfile February 7, 2024

Medexus Schedules Third Fiscal Quarter 2024 Conference Call

Newsfile January 30, 2024

Health Canada accepts Medexus drug for review

Trevor Abes  January 8, 2024

Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine

Newsfile January 8, 2024

Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

Newsfile November 8, 2023

Medexus Schedules Second Fiscal Quarter 2024 Conference Call

Newsfile November 1, 2023

Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering

Newsfile October 17, 2023
View More News ››

Opinion & Analysis (TSX:MDP)

VIDEO: Focused on Children's Medicine in an Underserved Market

BTV-Business Television June 8, 2016

Pediapharm (V.PDP) is a very attractive takeover candidate, Stockhouse poster says

Stockhouse Editorial April 20, 2015
View More Opinion ››

Bullboard Posts (TSX:MDP)

RE:Trend Continues

He is just trying to earn a living, there isn't any truth out of him
Napcoo - March 29, 2024

Trend Continues

March26th Equity Guru/Chris Parry writes up the company. Another company suckered out of their money by this scam out-fit. Stocks do...
TheMedia - March 29, 2024

RE:RE:Ixinity replacement therapy

Gene therapy needs time to verify the long term results, giving replacement therapy such as ixinity a break https://www.ema.europa.eu/en...
Napcoo - March 28, 2024

RE:RE:Ixinity replacement therapy

FDA-approved gene therapies In November 2022, the Food and Drug Administration approved Hemgenix, CSL Behring's hemophilia B gene...
Napcoo - March 28, 2024

RE:Ixinity replacement therapy

How much they've spent on ixinity? A lot, https://hemophilianewstoday.com/news/in-potential-100m-deal-medexus-acquires-global...
Napcoo - March 28, 2024

Ixinity replacement therapy

Cost per patient per year should be above $200k, while Gene therapy should be above $2mln, per person, one time cost, this is why MDP...
Napcoo - March 28, 2024
View more Bullboard ››

Nexera Energy Inc

Nexera Energy Inc

Nexera Energy Inc. is a Canada-based energy company with oil producing properties in southwest Texas. The Company is engaged ...
View More »